Scott B. Ullem sold $837k of EW
CVP, Chief Financial Officer at Edwards Lifesciences Corp. 11,250 shares at an average of $74.40, traded May 9, 2025, filed May 9, 2025.
Score components
- +22RoleCFO
- +23Trade size$837k at market
- +5Share of holdings soldSold 21% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001225208-25-004942, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 7, 2025 | FTax withholding Common Stock10b5-1 | -1,406 | $74.92 | $105k | 27,698 | May 9, 2025 |
| May 8, 2025 | AGrant or award Common Stock10b5-1 | +13,400 | $0.00 | $0 | 41,098 | May 9, 2025 |
| May 9, 2025 | MOption exercise Common Stock10b5-1 | +11,250 | $45.28 | $509k | 52,348 | May 9, 2025 |
| May 9, 2025 | SOpen-market sale Common Stock10b5-1 | -11,250 | $74.40 | $837k | 41,098 | May 9, 2025 |
| May 8, 2025 | AGrant or award Employee Stock Option (Right to Acquire)derivative10b5-1 | +75,200 | $0.00 | $0 | 75,200 | May 9, 2025 |
| May 8, 2025 | AGrant or award Performance Rightsderivative10b5-1 | +13,400 | $0.00 | $0 | 13,400 | May 9, 2025 |
| May 9, 2025 | MOption exercise Employee Stock Option (Right to Acquire)derivative10b5-1 | -11,250 | $0.00 | $0 | 0 | May 9, 2025 |
Related signals
Other insiders at Edwards Lifesciences Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $53k 619 shares | -2% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, TAVR | $54k 619 shares | -2% | |
| 13Weak | Edwards Lifesciences Corp | Larry L Wood Global President TAVR & Surg | $673k 8,950 shares | -4% | |
| 65Notable | Edwards Lifesciences Corp | Bernard J Zovighian CEO | $1.3M 17,066 shares | -67% | |
| 22Weak | Edwards Lifesciences Corp | Donald E Bobo Jr CVP,Strategy/Corp Development | $199k 2,570 shares | -5% | |
| 40Moderate | Edwards Lifesciences Corp | Daveen Chopra CVP, TMTT | $113k 1,500 shares | -4% | |
| 30Weak | Edwards Lifesciences Corp | Wayne Markowitz GM & SVP, Surgical | $20k 268 shares | -3% | |
| 0Weak | Edwards Lifesciences Corp | Daniel J. Lippis CVP, JAPAC | $25k 330 shares | -1% | |
| 22Weak | Edwards Lifesciences Corp | Bernard J Zovighian CEO | $448k 5,980 shares | -9% | |
| 13Weak | Edwards Lifesciences Corp | Donald E Bobo Jr CVP,Strategy/Corp Development | $663k 9,500 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.